Vinati Organics share price gained around 24 percent in 2020. The multibagger has compounded annually at around 28 percent between 1995 and 2020 as the company’s net profit grew around 24 percent.

Share Market Live

NSE

Vinati Organics’ Managing Director Vinati Saraf Mutreja told CNBC-TV18 that the company has applied under the pharma PLI scheme.

“We have applied under the pharma PLI scheme particularly for the intermediate PAP which we were working on earlier also. But I wouldn’t rely just on the PLI scheme or PAP project because we haven’t heard anything from the PLI scheme. Also it is still unclear whether we will be doing that investment even though the demand is there, India is importing a lot of PAP from China.”

On the growth in FY21, Vinati said, “In Q4 we will be as good as pre-COVID levels, Q1 pharma products were doing well which has stabilised now so net-net for FY21 we would be say about 10-15 percent below FY20. Again in FY22, because of the expansions and because of ATBS also going back to pre-COVID levels one can expect 20-25 percent growth from FY21.”

On revenues, she said, “The new product itself have a potential of say Rs 400-500 crore plus the existing ATBS, we are also expanding personal care line, ATBS will come back on stream, so all of that combined gives you a total of close to Rs 1,800-1,900 crore.”

Watch the video for more.

(Edited by : Ajay Vaishnav)

First Published:Jan 1, 2021 1:02 PM IST